VIVUS Lowered to Underperform at Bank of America (VVUS)
VIVUS (NASDAQ:VVUS) was downgraded by stock analysts at Bank of America from a “neutral” rating to an “underperform” rating in a report issued on Tuesday, Stock Ratings Network.com reports. They currently have a $6.00 target price on the stock, down from their previous target price of $11.00. Bank of America’s target price points to a potential downside of 11.11% from the company’s current price.
The analysts wrote, “We lowered our DCF-derived PO to $6 (from $11) and our rating to Underperform (from Neutral) following changes to our model to incorporate lowered expectations that VVUS will be able to secure a quality partner and favorable terms. We continue to believe a partner with broad primary care reach and the budget for DTC advertising is essential to drive an inflection in sales and maximize the potential of Qsymia, but we found management’s tone on finding a partner in 2014 to be negative. 4Q13 results of $7.7mn in Qsymia sales were disappointing in our view and illustrate the limited reach of VVUS’ 150 rep sales force. We believe VVUS is negotiating from a position of weakness due to flattish script trends in spite of free/discount drug programs (59% of scripts in 4Q). Our peak sales estimate is now $1bn in 2021 (prev. $1.8bn) and still assumes a partnership. The cost of the CVOT (~$200mn) heightens the need for a partner, and weakens VVUS’ position.”
VIVUS (NASDAQ:VVUS) traded down 13.19% on Tuesday, hitting $5.86. 14,132,222 shares of the company’s stock traded hands. VIVUS has a one year low of $5.77 and a one year high of $15.62. The stock has a 50-day moving average of $7. and a 200-day moving average of $9.59. The company’s market cap is $596.0 million.
VIVUS (NASDAQ:VVUS) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.23. The company had revenue of $44.06 million for the quarter, compared to the consensus estimate of $28.20 million. On average, analysts predict that VIVUS will post $-1.40 earnings per share for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.